Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 13/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | ALDH5A1 | P51649 | 2/20 | 0.61 |
| ▸ | ABAT | P80404 | 2/20 | 0.61 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL856737 | 1.00 | APP (0.63) | APPALDH1A1ALDH5A1ABATTRIM24 | |
| SCHEMBL24445666 | 0.86 | ALDH1A1 (0.61) | APPALDH1A1ALDH5A1ABATTRIM24 | |
| SCHEMBL6442449 | 0.85 | ALDH1A1 (0.56) | APPALDH1A1ALDH5A1ABATTRIM24 | |
| SCHEMBL6445440 | 0.85 | ALDH1A1 (0.56) | APPALDH1A1ALDH5A1ABATTRIM24 | |
| SCHEMBL21095690 | 0.82 | TRPA1 (0.61) | APPALDH1A1ALDH5A1ABATTRIM24 | |
| SCHEMBL8466367 | 0.82 | ALDH1A1 (0.66) | APPALDH1A1ALDH5A1ABATTRIM24 | |
| SCHEMBL11971265 | 0.80 | APP (0.78) | APPKDM4E | |
| SCHEMBL11971260 | 0.80 | APP (0.78) | APPKDM4E | |
| SCHEMBL3621190 | 0.80 | ALDH1A1 (0.44) | APPALDH1A1ALDH5A1ABATTRIM24 | |
| SCHEMBL22555972 | 0.79 | APP (0.76) | APPALDH1A1HPGDTDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746861-A1 | BIS(PHENYLMETHYLENE)CYCLOALKANONES AND THEIR HETEROCYCLIC ANALOGUES AND THEIR USE AS MEDICAMENTS, FOR THE TREATMENT OR PREVENTION OF PROTEINOPATHIES | Ustav Organicke Chemie a Biochemie AV CR v.v.i. (CZ) | 2026-05-27 | — | — | EP | disclosed |
| EP-4561975-A1 | FTO INHIBITORS | RPXDS Co., Ltd (CN) | 2025-06-04 | — | — | EP | disclosed |
| CN-119752318-A | Photosensitive polyimide coating adhesive and preparation method and application thereof | 波米科技有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119546566-A | FTO inhibitors | 瑞璞鑫(苏州)生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2025021237-A1 | BIS(PHENYLMETHYLENE)CYCLOALKANONES AND THEIR HETEROCYCLIC ANALOGUES AND THEIR USE AS MEDICAMENTS, FOR THE TREATMENT OR PREVENTION OF PROTEINOPATHIES | Ustav Organicke Chemie A Biochemie AV CR v.v.i. (CZ) | 2025-01-30 | — | — | WO | disclosed |
| US-20250011285-A1 | CYP11A1 INHIBITORS | ORION CORPORATION (FI) | 2025-01-09 | — | — | US | disclosed |
| WO-2024022491-A1 | FTO INHIBITORS | RPXDS CO., LTD (CN) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023024425-A1 | TRIAZOLONE COMPOUND AND MEDICINAL USE THEREOF | 中国药科大学 | 2023-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011285-A1 | CYP11A1 INHIBITORS | CYP11B1, CYP19A1, CYP11B2 | APP 2085/4885ALDH1A1 188/4885ALDH5A1 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.